Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.

导出 OA

翻译打印收藏纠错

作者： Honghe,Wan ^[1] ; Gretchen M,Schroeder ^[1] ; Amy C,Hart ^[1] ; Jennifer,Inghrim ^[1] ; James,Grebinski ^[1] ; John S,Tokarski ^[1] ; Matthew V,Lorenzi ^[1] ; Dan,You ^[1] ; Theresa,Mcdevitt ^[1] ; Becky,Penhallow ^[1] ; Ragini,Vuppugalla ^[1] ; Yueping,Zhang ^[1] ; Xiaomei,Gu ^[1] ; Ramaswamy,Iyer ^[1] ; Louis J,Lombardo ^[1] ; George L,Trainor ^[1] ; Stefan,Ruepp ^[1] ; Jonathan,Lippy ^[1] ; Yuval,Blat ^[1] ; John S,Sack ^[1] ; Javed A,Khan ^[1] ; Kevin,Stefanski ^[1] ; Bogdan,Sleczka ^[1] ; Arvind,Mathur ^[1] ; Jung-Hui,Sun ^[1] ; Michael K,Wong ^[1] ; Dauh-Rurng,Wu ^[1] ; Peng,Li ^[1] ; Anuradha,Gupta ^[1] ; P N,Arunachalam ^[1] ; Bala,Pragalathan ^[1] ; Sankara,Narayanan ^[1] ; Nanjundaswamy,K C ^[1] ; Prakasam,Kuppusamy ^[1] ; Ashok V,Purandare ^[1]

作者单位： Bristol-Myers Squibb R&D , US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States. ^[1]

关键词 BMS-911543 JAK2 myeloproliferative neoplasm selective inhibitor structure-guided design

DOI 10.1021/acsmedchemlett.5b00226

PMID 26288683

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交